Drug profile · INN
tafluprost
ZIOPTAN
tafluprost (ZIOPTAN) is a prostanoid fp receptor agonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — tafluprost
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
tafluprost (ZIOPTAN) is a prostanoid fp receptor agonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Prostanoid FP receptor agonist
Primary target: Prostaglandin F2-alpha receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Related & competitor drugs
Frequently asked questions
What is tafluprost?
tafluprost (ZIOPTAN) is a prostanoid fp receptor agonist. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for tafluprost?
ZIOPTAN is a marketed brand name for tafluprost. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tafluprost?
tafluprost has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.